Scholarlink

<p>Given the heterogeneity of the tumor microenvironment (TME), neoadjuvant immunotherapy combined with chemotherapy benefits only a subset of lung adenocarcinoma (LUAD) patients, and the mechanisms of resistance remain unclear. Transfer RNA-derived small RNAs (tsRNAs) are a new class of non-coding RNAs that participate in the remodeling of the TME. Using high-throughput small RNA microarray analysis, we found elevated expression of tsRNA 3′tiRNA-AlaCGC in tumors of LUAD patients resistant to neoadjuvant therapy, and negatively correlated with the poor prognosis in LUAD patients. Furthermore, we discovered that tumor-derived exosome carrying 3′tiRNA-AlaCGC target fibroblasts to induce a senescence-associated secretory phenotype (SASP) by inhibiting FOXO3, and activating the TGF-β/Smad3 pathway, thereby increasing Galectin-9 secretion; both SASP and Galectin-9 induce synthetically dysfunction of cytotoxic CD8<sup>+</sup> T cells. In vivo experiments revealed that high expression of 3′tiRNA-AlaCGC led to decrease infiltration and diminished cytotoxic function of CD8<sup>+</sup> T cells in tumors of C57BL/6 mice, resulting in anti-PD-L1 therapy resistance. Collectively, our research underscores the immunosuppressive role of 3′tiRNA-AlaCGC in LUAD, offering insights into its molecular traits and aiding personalized treatment strategy development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumor-derived exosomal tsRNA 3′tiRNA-AlaCGC in promoting fibroblast senescence and Galectin-9 secretion to induce immune tolerance in lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Guangyin Zhao,
  • Yuchen Zhang,
  • Hongyu Zhang,
  • Yifan Guo,
  • Chang Xu,
  • Di Ge,
  • Jie Gu

摘要

Given the heterogeneity of the tumor microenvironment (TME), neoadjuvant immunotherapy combined with chemotherapy benefits only a subset of lung adenocarcinoma (LUAD) patients, and the mechanisms of resistance remain unclear. Transfer RNA-derived small RNAs (tsRNAs) are a new class of non-coding RNAs that participate in the remodeling of the TME. Using high-throughput small RNA microarray analysis, we found elevated expression of tsRNA 3′tiRNA-AlaCGC in tumors of LUAD patients resistant to neoadjuvant therapy, and negatively correlated with the poor prognosis in LUAD patients. Furthermore, we discovered that tumor-derived exosome carrying 3′tiRNA-AlaCGC target fibroblasts to induce a senescence-associated secretory phenotype (SASP) by inhibiting FOXO3, and activating the TGF-β/Smad3 pathway, thereby increasing Galectin-9 secretion; both SASP and Galectin-9 induce synthetically dysfunction of cytotoxic CD8+ T cells. In vivo experiments revealed that high expression of 3′tiRNA-AlaCGC led to decrease infiltration and diminished cytotoxic function of CD8+ T cells in tumors of C57BL/6 mice, resulting in anti-PD-L1 therapy resistance. Collectively, our research underscores the immunosuppressive role of 3′tiRNA-AlaCGC in LUAD, offering insights into its molecular traits and aiding personalized treatment strategy development.